Issues Archive – Cell Therapy News

Neon Therapeutics Enters Collaborative Research Agreement with the Netherlands Cancer Institute Neon Therapeutics announced that the company has entered into a collaborative research agreement with the Netherlands Cancer Institutes (NKI) Antoni van Leeuwenhoek Hospital and the Amsterdam Biotherapeutics Unit. Under the terms of the agreement, Neon Therapeutics and NKI will combine complementary capabilities to develop personalized T cell therapeutics. [Neon Therapeutics] PressRelease

Juno Therapeutics, Seattle Cancer Care Alliance and Fred Hutchinson Cancer Research Center Announce New Immuno-Oncology Clinical Trials Unit Juno Therapeutics, Inc. and Fred Hutchinson Cancer Research Center announced the creation of a new, best-in-class clinical trials unit dedicated to immuno-oncology. [Juno Therapeutics, Inc.] PressRelease

OncBioMune Continuing Phase I Trial, While Initiating Phase II Trial of ProscaVax for Prostate Cancer OncBioMune Pharmaceuticals, Inc. reported positive results from its Phase I clinical trial of ProscaVax, the companys novel cancer vaccine for prostate cancer. [OncBioMune Pharmaceuticals, Inc.] PressRelease

Asterias Biotherapeutics Announces Successful End-of-Phase II Meeting with FDA for AST-VAC1 Asterias Biotherapeutics, Inc. announced the successful completion of an End-of-Phase II meeting with the U.S. Food and Drug Administration (FDA) for AST-VAC1, its investigational therapy targeting acute myeloid leukemia. [Asterias Biotherapeutics, Inc.] PressRelease

Capricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial Capricor Therapeutics, Inc. announced continuing enrollment of, and the treatment of the first patient with Duchenne Muscular Dystrophy-related cardiomyopathy with CAP-1002 in the HOPE-Duchenne Phase I/II clinical trial. [Capricor Therapeutics, Inc.] PressRelease

National Institutes of Healths NIAID Initiating Dose Evaluation Studies in Animal Models of Pluristems PLX-R18 in the Treatment of Acute Radiation Syndrome Pluristem Therapeutics Inc. announced that the National Institute of Allergy and Infectious Diseases (NIAID) will initiate studies in large animals to evaluate dosing for Pluristems PLX-R18 as a medical counter measure in the treatment of the hematologic components of Acute Radiation Syndrome. [Pluristem Therapeutics Inc.] PressRelease

TapImmune Receives Notice of Allowance on U.S. Patent Claims for PolyStart Next-Generation T-Cell Vaccine TapImmune, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application entitled, A chimeric nucleic acid molecule with non-AUG initiation sequences. The patent claims are for the Companys proprietary PolyStart technology which is a platform for the next-generation vaccine technology for the treatment of cancer or infectious diseases. [TapImmune, Inc.] PressRelease

CAR Trials Drive Leukemia and Lymphoma Treatment in New Direction Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells one of the immune systems primary weapons to treat three different types of blood cancer that often defy existing therapies. [UC San Diego Health] PressRelease

La Jolla Institute Receives $5 Million Gift from Pfizer La Jolla Institute for Allergy and Immunology has received a $5 million gift, which will help establish the Mission Support for Cancer Immunology and Oncology Research. The Institute will use the majority of the funds to establish the Pfizer Endowed Chair in Cancer Immunology and Oncology and support research on the immune system and oncology. [La Jolla Institute for Allergy and Immunology] PressRelease

True North Therapeutics Receives Orphan Drug Designation in the European Union for TNT009 for the Treatment of Autoimmune Hemolytic Anemia, including Cold Agglutinin Disease (CAD) True North Therapeutics announced that the European Medicines Agency granted Orphan Drug Designation for TNT009 for the treatment of autoimmune hemolytic anemia including CAD, in which autoantibodies target and destroy red blood cells, causing anemia, fatigue and potentially fatal thrombosis. [True North Therapeutics, Inc.] PressRelease

TxCell Launches New Manufacturing Process Development Laboratories and Technology Transfer Academy TxCell SA announced the launch of its new process industrialization laboratories and technology transfer academy facilities in Sophia Antipolis, France. [TxCell SA] PressRelease

Link:
Issues Archive - Cell Therapy News